Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,449 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABI-007(Abraxane) Clear all
Completed Phase 2 Interventional Results available

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00487669
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
paclitaxel poliglumex, pemetrexed
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 19, 2026, 5:05 AM EDT
Terminated No phase listed Observational

Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer

NCT00537173
View directory record Official record
Conditions
Breast Cancer
Interventions
Core Biopsy, Blood Collection, Paclitaxel, Avastin
Procedure · Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Bloomington, Indiana • Indianapolis, Indiana • Lafayette, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Results available

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

NCT02122770
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 19, 2026, 5:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

NCT04711824
View directory record Official record
Conditions
Breast Cancer, Brain Metastases, Adult
Interventions
Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy
Drug · Radiation
Lead sponsor
Colette Shen
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

NCT00675259
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, carboplatin, nab-paclitaxel, Surgery, Adjuvant chemotherapy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 19, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

NCT00407407
View directory record Official record
Conditions
Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
Interventions
ABI-007, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer

NCT00439608
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Cetuximab,Paclitaxel, Carboplatin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer

NCT00581971
View directory record Official record
Conditions
Cancer
Interventions
celecoxib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Results available

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

NCT02001974
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Paclitaxel+Reparixin
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Fairway, Kansas • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00025480
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, tipifarnib, radiation therapy
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 19, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional Results available

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

NCT00718523
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479, AMG 479 Placebo
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
23
States / cities
Alhambra, California • Burbank, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 19, 2026, 5:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

NCT03602859
View directory record Official record
Conditions
Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Interventions
Niraparib, Dostarlimab (TSR-042), Standard of care, Dostarlimab-Placebo, Niraparib-Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
65
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

NCT02725268
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Paclitaxel, Sapanisertib, MLN1117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Greenbrae, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 19, 2026, 5:05 AM EDT
Recruiting Early Phase 1 Interventional

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

NCT05691010
View directory record Official record
Conditions
Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma, Endometrial Carcinoma Stage III
Interventions
Intensity-modulated radiation therapy, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 19, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

NCT00003624
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Sarcoma
Interventions
amifostine trihydrate, cisplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 19, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

NCT01407562
View directory record Official record
Conditions
Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female
Interventions
Pazopanib, Paclitaxel, Carboplatin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

NCT01959490
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

NCT03517449
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
25
States / cities
Phoenix, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 19, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

NCT03520790
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Nab-paclitaxel, Paricalcitol, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 19, 2026, 5:05 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

NCT04339738
View directory record Official record
Conditions
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
170
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Early Phase 1 Interventional

Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer

NCT01263613
View directory record Official record
Conditions
Breast Cancer
Interventions
tumor biopsy and blood draw
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer

NCT00378313
View directory record Official record
Conditions
Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Locally Advanced
Interventions
gemcitabine, epirubicin, paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2008 · Synced Oct 19, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional Results available

Treatment With Nab-paclitaxel in Cutaneous SCC

NCT02076243
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 19, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

NCT00606125
View directory record Official record
Conditions
Neoplasms
Interventions
Nexavar (Sorafenib, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
New Haven, Connecticut • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Oct 19, 2026, 5:05 AM EDT